[HTML][HTML] A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) …
Thiazolidinedione class of anti-diabetic drugs which are known as peroxisome proliferator-
activated receptor γ (PPARγ) ligands have been used to treat metabolic disorders, but
thiazolidinediones can also cause several severe side effects, including congestive heart
failure, fluid retention, and weight gain. In this study, we describe a novel synthetic PPARγ
ligand UNIST HYUNDAI Compound 1 (UHC1) that binds tightly to PPARγ without the
classical agonism and which blocks cyclin-dependent kinase 5 (CDK5)-mediated PPARγ …
activated receptor γ (PPARγ) ligands have been used to treat metabolic disorders, but
thiazolidinediones can also cause several severe side effects, including congestive heart
failure, fluid retention, and weight gain. In this study, we describe a novel synthetic PPARγ
ligand UNIST HYUNDAI Compound 1 (UHC1) that binds tightly to PPARγ without the
classical agonism and which blocks cyclin-dependent kinase 5 (CDK5)-mediated PPARγ …